Episode Details

Back to Episodes
Can Glaucoma Damage Be Reversed? First Human Epigenetic Reprogramming Trial Targets the Optic Nerve

Can Glaucoma Damage Be Reversed? First Human Epigenetic Reprogramming Trial Targets the Optic Nerve

Published 3 months ago
Description

This audio article is from VisualFieldTest.com.

Read the full article here: https://visualfieldtest.com/en/can-glaucoma-damage-be-reversed-first-human-epigenetic-reprogramming-trial-targets-the-optic-nerve

Test your visual field online: https://visualfieldtest.com

Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support

Excerpt:

Can Glaucoma Damage Be Reversed? First Human Epigenetic Reprogramming Trial Targets the Optic Nerve Updated August 11, 2026 Bottom line ER-100 is the first human clinical trial of a partial epigenetic reprogramming therapy, but it is not yet evidence that glaucoma damage can be reversed in people. Life Biosciences is testing ER-100 in a small, first-in-human Phase 1 study involving adults with open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy. The treatment delivers genetic instructions for three transcription factors—OCT4, SOX2, and KLF4, collectively called OSK—to retinal ganglion cells using an adeno-associated virus type 2 vector. Oral doxycycline is then used for eight weeks to activate the therapeutic genes. [ClinicalTrials.gov study record] () The scientific idea is fundamentally different from conventional glaucoma treatment. Instead of lowering intraocular pressure, ER-100 is intended to make damaged but living retinal ganglion cells behave more like younger, healthier cells. The preclinical evidence is unusually ambitious: studies in mice reported retinal ganglion cell survival, optic nerve axon growth, improved electrical retinal responses, and improved visual behavior. Company-presented nonhuman-primate data reported recovery of pattern electroretinogram responses and improved optic nerve axon survival after an experimental optic nerve stroke. However, the primate findings have been publicly described mainly through company disclosures and a 2023 Association for Research in Vision and Ophthalmology presentation rather than a detailed, independent, peer-reviewed clinical-efficacy publication. [Nature study] () [Life Biosciences primate disclosure] () As of August 11, 2026, no human vision benefit, epigenetic reset, retinal ganglion cell regeneration, or long-term safety result has been publicly reported. Life Biosciences has confirmed that the first participant was dosed, but the trial remains an early safety study with no results posted on ClinicalTrials.gov. [Life Biosciences first-dose announcement] () [ClinicalTrials.gov record] () The fairest conclusion is: > Glaucoma has not yet entered the era of proven optic-nerve restoration. It has entered the era of the first credible human experiment testing whether optic-nerve cells can be rejuvenated rather than merely protected. --- Why current glaucoma treatments do not reverse damage Glaucoma damages retinal ganglion cells, the nerve cells that collect visual information from the retina. Their long axons form the optic nerve and carry signals to the brain. Once retinal ganglion cells and their axons are permanently lost, current treatments cannot replace them. Standard treatments—including eye drops, laser treatment, and glaucoma surgery—primarily reduce intraocular pressure. Lowering pressure can slow or prevent additional optic nerve damage, but it does not normally restore lost visual field. [National Eye Institute] () [American Academy of Ophthalmology patient information] () This is why glaucoma care is generally described as preservation rather than restoration. Lowering pressure remains the only proven treatment strategy for controlling ordinary open-angle glaucoma, although disease progression can sometimes continue even when pressure is considered acceptable. [Nation

Listen Now

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us